Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
There are a number of potential implications for the field of Alzheimer's disease (AD) stemming from the global spread of SARS-CoV-2. Neuroinflammation is known to be a prominent feature of neurodegeneration and plays a major role in AD pathology. Immune response and excessive inflammation in COVID-19 may also accelerate the progression of brain inflammatory neurodegeneration, and elderly individuals are more susceptible to severe outcomes after SARS-CoV-2 infection. Individuals with type 2 diabetes (T2D) are at an increased risk for AD as well as severe outcomes after SARS-CoV-2 infection. Genetic and socioeconomic factors influencing the rates of T2D, AD, and COVID-19 severity may create an exceptionally high-risk profile for certain demographics such as African Americans and Hispanic Americans. Type I interferon response plays an important role in both host response to viral infection, as well as AD pathology and may be a sensible therapeutic target in both AD and COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761 · cited 1×
“Severe outcomes after SARS-CoV-2 infection are often associated with a “cytokine storm” of pronounced inflammation [12].”
BackgroundA first case of meningitis/encephalitis associated with SARS-Coronavirus-2
Moriguchi, T., Harii, N., Goto, J., Harada, D., Sugawara, H., Takamino, J., Ueno, M., Sakata, H., Kondo, K., Myose, N., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.062 · Cited by 2,024 · cited 1×
“The acute neurological complications resulting from SARS-CoV-2 infection include meningitis and acute necrotizing encephalopathy, as well as gustatory and olfactory impairments [20, 22, 23].”
BackgroundCOVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features
Poyiadji, N., Shahin, G., Noujaim, D., Stone, M., Patel, S., & Griffith, B. (2020) · Radiology · doi:10.1148/radiol.2020201187 · Cited by 1,505
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267 · cited 2×
“The “cytokine storm” associated with COVID-19 has been associated with an increase of pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1 (IL-1), and IL-6 all of which have been identified to be increased in the elderly [13, 14].”
BackgroundReadhead, B., Haure-Mirande, J.-V., Funk, C. C., Richards, M. A., Shannon, P., Haroutunian, V., Sano, M., Liang, W. S., Beckmann, N. D., Price, N. D., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.023 · Cited by 708 · cited 1×
“Readhead and colleagues found increased levels of human herpesvirus 6 and human herpesvirus 7 across several regions in postmortem brains of AD patients [19].”
BackgroundEimer, W. A., Vijaya Kumar, D. K., Navalpur Shanmugam, N. K., Rodriguez, A. S., Mitchell, T., Washicosky, K. J., György, B., Breakefield, X. O., Tanzi, R. E., & Moir, R. D. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.030 · Cited by 674
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease
Roy, E. R., Wang, B., Wan, Y.-W., Chiu, G., Cole, A., Yin, Z., Propson, N. E., Xu, Y., Jankowsky, J. L., Liu, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133737 · Cited by 563
Neurons produce type I interferon during viral encephalitis
Delhaye, S., Paul, S., Blakqori, G., Minet, M., Weber, F., Staeheli, P., & Michiels, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602460103 · Cited by 266
Shared genetic etiology underlying Alzheimer’s disease and type 2 diabetes
Hao, K., Di Narzo, A. F., Ho, L., Luo, W., Li, S., Chen, R., Li, T., Dubner, L., & Pasinetti, G. M. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.006 · Cited by 84 · cited 1×
“Type 2 diabetes (T2D), the most common form of diabetes, has also been linked with an increased predisposition to Alzheimer’s disease (AD) through shared genetic etiologies [7].”
Background
Cited by
Infectious agents and Alzheimer's disease
Piekut, T., Hurła, M., Banaszek, N., Szejn, P., Dorszewska, J., Kozubski, W., & Prendecki, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2102073 · Cited by 123
The impact of dementia on the clinical outcome of COVID-19: a systematic review and meta-analysis
Liu, N., Sun, J., Wang, X., Zhao, M., Huang, Q., & Li, H. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-201016 · Cited by 110
“One of the reasons that patients with dementia are at higher risk may be due to the presence of higher baseline inflammation [30].”
BackgroundDamiano, R. F., Guedes, B. F., de Rocca, C. C., de Pádua Serafim, A., Castro, L. H. M., Munhoz, C. D., Nitrini, R., Filho, G. B., Miguel, E. C., Lucchetti, G., et al. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01286-4 · Cited by 98
Neuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
COVID-19 as a Risk Factor for Alzheimer’s Disease
Golzari-Sorkheh, M., Weaver, D. F., & Reed, M. A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220800 · Cited by 39
Metadata
- Authors
- Naughton, S. X., Raval, U., & Pasinetti, G. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2020-06-30
- Volume
- 76
- Issue
- 1
- Pages
- 21-25
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W3034465868
- Cited by
- 138
- References
- 11
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.